XML 69 R58.htm IDEA: XBRL DOCUMENT v3.25.3
FAIR VALUE MEASUREMENTS - Narrative (Details)
9 Months Ended
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Aug. 04, 2025
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2024
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Contingent consideration $ 284,113,000 $ 283,231,000   $ 275,408,000 $ 282,212,000 $ 277,921,000 $ 288,657,000
Contingent consideration liability, measurement input         0.90    
Business Combination, Contingent Consideration, Liability, Current         $ 19,700,000    
Business Combination, Contingent Consideration, Liability, Noncurrent         262,500,000    
Equity Method Investments, Fair Value Disclosure 7,383,000       7,488,000    
Other Investment Not Readily Marketable, Fair Value 50,941,000 52,227,000     50,448,000    
Venture capital investment fund              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Committed capital 18,000,000            
Committed capital callable 9,800,000            
Equity Method Investments, Fair Value Disclosure $ 7,400,000       $ 7,500,000    
Freenome Holdings, Inc              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Investment Owned, Cost     $ 50,000,000.0        
Investment Interest Rate 500.00%            
Investment owned, at fair value $ 50,400,000            
Product development and other milestone-based payments | Weighted average | Measurement Input, Probability of Success              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Contingent consideration liability, measurement input 0.90            
Product development and other milestone-based payments | Weighted average | Measurement Input, Present-value Factor              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Contingent consideration liability, measurement input 0.056       0.062    
Foreign exchange forward              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Derivative, notional amount $ 56,400,000       $ 44,200,000    
Derivative, fair value 0       0    
Gain (Loss) on derivative instruments, net, pretax 0 $ 0          
Fair Value, Recurring              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Contingent consideration 284,113,000       282,212,000    
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Contingent consideration 284,113,000       282,212,000    
Thrive, Ashion and OmicEra | Fair value              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Contingent consideration         $ 282,200,000    
Resolution Bioscience acquisition adjustments | Fair value              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Contingent consideration $ 284,100,000